Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70139 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Michael Thy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Intensive et Réanimation Infectieuse, Hôpital Bichat Claude-Bernard, AP-HP, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents, Continuous Renal Replacement Therapy. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Baxter International Foundation, Société de Réanimation de Langue Française.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in vitro data derived from two experiments with continuous venovenous hemodiafiltration (CVVHDF) simulation and a comparison with a previously published in vivo case report. The results highlight the importance of therapeutic drug monitoring and the need for higher dosing or continuous infusion of ceftazidime–avibactam in critically ill children under crontinuous renal replacement therapy (CRRT).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service de Médecine Intensive et Réanimation Infectieuse, Hôpital Bichat Claude-Bernard, AP-HP, Université Paris Cité, Paris, France.
- UMR 1343, Evaluation Des thérapeutiques et Pharmacologie périnatale et pédiatrique, INSERM, Université Paris Cité, Paris, France.
- UMR 1137, IAME, INSERM, Université Paris Cité, Paris, France.
- Service de Réanimation et Surveillance Continue médicochirurgicales, Hôpital Necker Enfants-Malades, AP-HP, Université Paris Cité, Paris, France.
- Service de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Université Paris Cité, Paris, France.
- Unité de Recherche Clinique-Centre D'investigation Clinique, CIC1419, Hôpital Cochin-Necker, AP-HP, Université Paris Cité, Paris, France.
ORCID-Profile: Michael Thy
Förderung
- Baxter International Foundation
- Société de Réanimation de Langue Française
Zitieren
APA
Thy, M., Debs, A., Lui, G., Froelicher-Bournaud, L., Tréluyer, J. M., & Oualha, M. (2025). Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70139
Vancouver
Thy M, Debs A, Lui G, Froelicher-Bournaud L, Tréluyer JM, Oualha M. Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70139
BibTeX
@article{Thy2025,
author = {Thy, Michael and Debs, Alexandre and Lui, Gabrielle and Froelicher-Bournaud, Leo and Tréluyer, Jean-Marc and Oualha, Mehdi},
title = {Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70139}
}
EUVIMED